Vir Biotechnology, Inc. (NASDAQ:VIR) Shares Sold by Barclays PLC

Barclays PLC lessened its stake in shares of Vir Biotechnology, Inc. (NASDAQ:VIR - Free Report) by 59.8% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 221,178 shares of the company's stock after selling 329,008 shares during the quarter. Barclays PLC owned about 0.16% of Vir Biotechnology worth $1,624,000 at the end of the most recent reporting period.

Several other hedge funds also recently bought and sold shares of VIR. Rhumbline Advisers grew its stake in Vir Biotechnology by 0.5% in the 4th quarter. Rhumbline Advisers now owns 236,681 shares of the company's stock worth $1,737,000 after acquiring an additional 1,288 shares during the period. PNC Financial Services Group Inc. grew its position in shares of Vir Biotechnology by 31.8% in the fourth quarter. PNC Financial Services Group Inc. now owns 8,288 shares of the company's stock valued at $61,000 after purchasing an additional 1,999 shares during the period. Teacher Retirement System of Texas increased its stake in Vir Biotechnology by 10.7% in the fourth quarter. Teacher Retirement System of Texas now owns 26,440 shares of the company's stock valued at $194,000 after purchasing an additional 2,556 shares during the last quarter. Invesco Ltd. lifted its position in Vir Biotechnology by 0.6% during the fourth quarter. Invesco Ltd. now owns 398,772 shares of the company's stock worth $2,927,000 after buying an additional 2,574 shares during the period. Finally, China Universal Asset Management Co. Ltd. boosted its stake in Vir Biotechnology by 11.1% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 29,202 shares of the company's stock worth $214,000 after buying an additional 2,922 shares during the last quarter. Hedge funds and other institutional investors own 65.32% of the company's stock.

Insider Buying and Selling

In other news, EVP Verneuil Vanina De sold 7,373 shares of the stock in a transaction that occurred on Wednesday, February 26th. The stock was sold at an average price of $9.14, for a total transaction of $67,389.22. Following the completion of the transaction, the executive vice president now directly owns 79,460 shares in the company, valued at approximately $726,264.40. This represents a 8.49 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director George A. Scangos sold 10,964 shares of the firm's stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $9.81, for a total transaction of $107,556.84. Following the sale, the director now directly owns 708,295 shares of the company's stock, valued at $6,948,373.95. The trade was a 1.52 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 99,611 shares of company stock valued at $663,525 in the last quarter. Company insiders own 15.60% of the company's stock.

Analysts Set New Price Targets

Several brokerages have recently weighed in on VIR. Barclays increased their price objective on shares of Vir Biotechnology from $26.00 to $31.00 and gave the stock an "overweight" rating in a report on Friday, February 28th. Morgan Stanley raised shares of Vir Biotechnology from an "equal weight" rating to an "overweight" rating and boosted their price objective for the company from $10.00 to $20.00 in a research note on Thursday, January 9th. HC Wainwright reaffirmed a "buy" rating and issued a $110.00 target price on shares of Vir Biotechnology in a research report on Friday, February 28th. The Goldman Sachs Group lowered their price target on Vir Biotechnology from $28.00 to $21.00 and set a "buy" rating for the company in a research report on Thursday, April 17th. Finally, JPMorgan Chase & Co. raised their price objective on Vir Biotechnology from $10.00 to $14.00 and gave the stock a "neutral" rating in a report on Thursday, January 9th. One analyst has rated the stock with a hold rating and six have assigned a buy rating to the company's stock. According to MarketBeat.com, Vir Biotechnology has a consensus rating of "Moderate Buy" and an average target price of $33.57.

Vir Biotechnology Stock Performance

Shares of VIR stock traded down $0.52 during trading hours on Tuesday, reaching $5.63. The company had a trading volume of 1,893,749 shares, compared to its average volume of 1,336,125. The company has a market capitalization of $777.30 million, a P/E ratio of -1.44 and a beta of 1.36. Vir Biotechnology, Inc. has a twelve month low of $4.95 and a twelve month high of $14.45. The stock's fifty day simple moving average is $6.49 and its 200 day simple moving average is $8.00.

Vir Biotechnology (NASDAQ:VIR - Get Free Report) last issued its quarterly earnings data on Wednesday, February 26th. The company reported ($0.76) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.85) by $0.09. Vir Biotechnology had a negative net margin of 678.40% and a negative return on equity of 36.71%. The company had revenue of $12.37 million during the quarter, compared to the consensus estimate of $8.14 million. As a group, equities analysts expect that Vir Biotechnology, Inc. will post -3.92 earnings per share for the current year.

Vir Biotechnology Company Profile

Vir Biotechnology, Inc, an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV).